rttnews.com
J&J Reports Positive Phase 3 Results For TREMFYA In Perianal Fistulizing Crohn's Disease
Cure8 flagged this item because the article title and available source metadata connect it to Crohn's disease, Guselkumab, IL-23 inhibitor, and Fistula. We do not yet have enough reliable article text to summarize the details.
This may be most useful for Adult patients and Patients with Perianal Disease following Crohn's disease, Guselkumab, IL-23 inhibitor, Fistula, and Research and clinical trials.
What To Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Guselkumab, IL-23 inhibitor, and Fistula. Use the original source link for the full details.
Trial findings can depend on who was enrolled, what outcomes were measured, and how long people were followed. The original source has the study details.
